TS-038701 — Modality: Small-molecule prodrug that targets the IL-6/STAT3 signaling pathway Stage of Development: Extensive in vitro and in vivo efficacy (3 MS models, incl. relapsing-remitting EAE); preliminary safety Patent Status: Pat. no. 11,420,946 (US); appl. 17/821,286 (US); appl. 18860926.7 (EP); app…

TS-037569 — The constant activation of Signal Transducer and Activator of Transcription 3 (STAT3) is frequently detected in many cancer patients with advanced diseases. About 80% of all cancers overexpress STAT3, including solid tumors, lymphoma, and leukemia. Constant activation of STAT3 activities in nonmal…